Kineta, Inc. Stock Price, News & Analysis

Welcome to our dedicated page for Kineta news (Ticker: KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.

Kineta, Inc. (historically trading as KA on Nasdaq and later as KANT on OTC Pink) generated a stream of news centered on its development of VISTA-targeted immunotherapies in oncology and the evolution of its corporate structure. Company press releases describe Kineta as a clinical-stage biotechnology company focused on novel immunotherapies that address cancer immune resistance, with a mission to develop next-generation treatments that transform patients’ lives.

Most of Kineta’s recent news coverage focused on KVA12123, its VISTA blocking immunotherapy and anti-VISTA monoclonal antibody. Updates included interim clinical data from the Phase 1/2 VISTA-101 trial in advanced solid tumors, reports of partial response and stable disease in combination cohorts with pembrolizumab, durable stable disease in monotherapy cohorts, and a favorable safety and tolerability profile without dose limiting toxicities or cytokine release syndrome–associated cytokines at reported dose levels. Additional items highlighted biomarker findings and scientific presentations at major conferences such as the American Association for Cancer Research and the Society for Immunotherapy of Cancer.

News items also documented corporate and strategic developments, including a significant restructuring in early 2024 to reduce expenses and preserve cash, suspension and later resumption of enrollment in the VISTA-101 trial, and Kineta’s exploration of strategic alternatives. Multiple releases describe an exclusivity and right of first offer agreement with TuHURA Biosciences for the potential acquisition of KVA12123 and related assets, as well as collaborative efforts to reopen and conduct the VISTA-101 study.

Another important category of news involved capital markets and listing status. Kineta announced its transition from Nasdaq to the OTC Pink Open Market, with the ticker symbol KANT, following a Nasdaq determination to delist the company’s common stock for not meeting certain listing requirements. Later regulatory filings report stockholder approval of mergers with TuHURA Biosciences and the subsequent deregistration of Kineta’s common stock.

Investors and observers using this news feed can review historical announcements on clinical progress, safety and efficacy signals from KVA12123, conference presentations, restructuring actions, financing-related developments, listing changes, and the merger process that led to Kineta, LLC becoming a wholly owned subsidiary of TuHURA.